Renin Angiotensin Aldosterone System Gene Polymorphisms among Type 2 Diabetic Patients with Retinopathy and Nephropathy Authors: Vaishali S. Pawar, Kailas D. Datkhile, Ajit V. Sontakke, Satyajeet K. Pawar, Prajakta S. Patil Published: 2024 ABSTRACT ABSTRACTIntroduction:Diversified pathways are associated with the advancement of type 2 diabetes mellitus (T2DM) towards retinopathy and nephropathy. Experimental data have suggested the role of renin-angiotensin-aldosterone system (RAAS) gene polymorphism in diabetic nephropathy (DN) patients. Since very few combined studies were done for RAAS genes in T2DM patients with DN and diabetic retinopathy (DR), we tried to explore the association of certain RAAS gene polymorphisms in them.Methods:Single nucleotide polymorphisms (SNPs), Met235Thr of angiotensinogen (AGT) gene, and insertion/deletion (ins/del) of angiotensin-converting enzyme (ACE) gene from RAAS pathway were studied using polymerase chain reaction (PCR) method in this cross-sectional study. T2DM patients diagnosed with nephropathy and retinopathy were selected (n = 125 each) consecutively and compared with T2DM patients without DN and/or DR. SPSS software was used for statistical analysis.Results:Considerably higher blood pressure, serum urea, and creatinine levels were found among DN patients. The DD genotype of ACE SNP was significantly higher in the DR and DN groups (OR: 2.87,95%CI: 1.48-5.56, P = 0.002 and OR: 2.36,95%CI: 1.23-4.53, P = 0.010) compared to the DM Group. In AGT Met235Thr SNP, the CC and TC genotypes were significantly increased in DN while only the TC genotype was significantly increased in the DR group.Conclusion:ACE ins/del and AGT Met235Thr SNPs were significantly related to the risk of development of nephropathy and retinopathy in T2DM patients. INTRODUCTION Among micro-vascular complications related to type 2 diabetes mellitus, diabetic nephropathy (DN) is the prominent contributor towards end-stage renal disease (ESRD) while diabetic retinopathy (DR) is an important reason for visual impairment worldwide.[1] Only 20–30% of type 2 diabetics presented with progressive renal disease[2] while advanced retinal disease is observed in more than 60% of patients within the first two decades of commencement of diabetes.[3] Because of the advancing nature of both the conditions they are considered as serious health problems. Clustering of these conditions in families suggests a genetic contribution yet basic molecular mechanisms are uncertain.[45] So there is a possibility of polymorphisms or mutations in many genes. Discovering variations in genes may help diagnose and intervene early in DN and DR. Out of the different genes concerned with different pathways, renin-angiotensin-aldosterone system (RAAS) gene polymorphisms have been notified in the progression of DN including DR, and have been studied in various populations.[678910] In the RAA system, angiotensinogen (AGT) is converted to angiotensin I by renin. Angiotensin-converting enzyme (ACE), which is also a component of RAAS converts angiotensin I into vasoconstrictor molecule angiotensin II. Angiotensin II (Ang II) is a strong vasoconstrictor and important in the regulation of systemic and renal circulation.[11] Thus mutations or polymorphisms in RAAS genes may be the reason for excessive production of Ang II or its availability leading to albuminuria, glomerulosclerosis, and ultimately development of DN.[12] Migdalis IN et al.[13] detected high circulating ACE levels in patients with proliferative DR. During the course of diabetes, high levels of renin and ACE activity may produce excess Ang II in the circulation and the eyes. Ang II as a potent vasoconstrictor may cause abnormalities in retinal blood vessels such as constriction of retinal arterioles, reduction in blood flow, increased local blood pressure, and ultimately increased permeability.[13] In the RAAS pathway, ACE ins/del and AGT Met235Thr gene polymorphisms are the most commonly investigated for connection with diabetic nephropathy. Expression of Ang II is implied to be controlled mainly by these polymorphisms, which may be linked to the risk of the progression of DN.[12] India had 74.9 million diabetic patients in 2021 and is expected to increase to 124.9 million by 2045.[14] Because of this increase, a subsequent upsurge of diabetes-associated complications is unavoidable. Though genetic studies in T2DM patients with DR and DN among the Indian population are available, very few combined studies have been done. Even with the studies, the relevance of these genes in the progression of DR remains unpredictable, not only because of the connection of multiple pathways in the pathogenesis but also due to genetic variation among different populations all over the world. Given the significance of genes of the RAAS pathway in the progression of DN and DR, an association of SNPs of ACE and AGT genes has been analyzed with DN and DR in T2DM patients in the present study. MATERIALS AND METHODS Selection of study population The study participants were screened from the Department of Ophthalmology, Medicine, a tertiary care hospital, and medical research center from December 2019 to January 2023. The investigations for this cross-sectional observational study were done in the Department of Biochemistry and Molecular Biology and Genetic Laboratory KIMS, Karad. The study by Prasad P et al.,[15] was referred to calculate sample size. The T2DM cases were divided into three groups. In each group, 125 patients with an age of more than 35 years were included. The diabetic patients without DR and/or DN (group 1 DM), patients with DR (group 2 DR), and patients with DN (group 3 DN) were recruited consecutively from the hospital. For DM, inclusion criteria were individuals with known cases of type 2 DM and >10 years of treatment without DN and/or DR. Patients with albuminuria >300 mg/gm creatinine, diagnosed as diabetic kidney disease by the department of nephrology with no evidence of moderate, severe non-proliferative DR (NPDR) or proliferative DR (PDR) were included in DN group. In the DR group, patients with all stages of retinopathy except mild DR and DN were recruited. Patients with age < 35 years, Type 1 DM or any other type of diabetes, liver disease, oncologic disease, thyroid disorders or other endocrine diseases, renal diseases due to other medical conditions, pregnant and lactating females, with mild NPDR, retinal vascular occlusions, glaucoma, and mature cataracts were excluded. Demographic data and clinical data were recorded in proforma for every study participant by taking interviews and from their medical record files. All patients underwent a full ophthalmic examination including fundus examination and diabetic retinopathy grading. Blood sampling and DNA extraction Appropriate vacutainer tubes were used to collect 10 ml fasting venous blood samples for biochemical and genetic assays. Using an auto analyzer, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), serum urea, and creatinine were estimated by standard biochemical methods. The DNA isolation kits were used for the isolation and purification of whole genomic DNA from the blood samples (HiPurA® Blood Genomic DNA Miniprep Purification Kit, HiMedia Laboratories Pvt Ltd., Thane, Maharashtra, India). Genotyping of polymorphisms of ACE and AGT genes The ACE ins/del and AGT Met235Thr polymorphisms were genotyped using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Primer sequences,[15] PCR conditions, and restriction enzymes with product size for SNPs in ACE and AGT genes are shown in Table 1. To assess the PCR amplification 2% agarose gel with ethidium bromide was used. For ACE ins/del polymorphism band at 190 bp suggested the presence of deletion (D) allele and the band at 490bp suggested the presence of insertion (I) allele. After gel electrophoresis, there were three genotypes: homozygous II (band at 490bp), homozygous DD (band at 190bp), and heterozygous ID (bands at 490bp and 190bp) as featured in Figure 1. PCR product of the AGT gene was digested with restriction enzyme BstUI at 60° C for 1 hour and the digested product was assessed using 3% agarose gel with ethidium bromide. For AGT Met235Thr SNP, Allele T was characterized by the presence of a 302 bp band, which was digested further into 278bp and 24bp fragments as allele C carriers. Thus there were three genotypes: homozygous TT (band at 302bp), homozygous CC (bands at 278bp and 24bp), and heterozygous TC (bands at 302bp, 278bp, and 24bp) as appeared in Figure 2. Table 1Primer sequences, PCR conditions, and restriction enzyme with product size for SNPs in ACE and AGT genesPolymorphismsPrimer sequences F: Forward primer R: Reverse primerPCR productAnnealing temp./Restriction enzyme/Allele sizesACEF: 5’- CTG GAG ACC ACT CCC ATC CTT TCT-3’490 bp60°C/Ins=490Ins/DelR: 5’- GAT GTG GGC ATC ACA TTC GTC AGA T-3Del=190AGTF: 5’- GAT GCG CAC AAG GTC CTG-3’302 bp60°C/BstUI/Met235ThrR: 5’- CAG GGT GCT GTC CAC ACT GGC TCG C-3’T=302 C=278, 24 Primer sequences, PCR conditions, and restriction enzyme with product size for SNPs in ACE and AGT genes Gel electrophoresis showing PCR products of ACE. Lane L- 100bp ladder, Lane1,2,7,9,10,12 - ID genotype (bands at 490bp and 190bp), Lane 3,5,6,11- II genotype (band at 490bp), Lane 4,8- DD genotype (band at 190bp) Gel electrophoresis showing PCR products of AGT. Lane L- 50bp ladder, Lane 1, 2, 5, 6, 10, 14 –TT genotype (band at 302bp), Lane 3,8,12- CC genotype (bands at 278bp and 24bp). Lane 4, 7 9, 11,13- TC genotype (bands at 302bp, 278bp and 24bp) Statistical analysis Data analysis was done with the help of SPSS software (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, USA NY: IBM Corp.). For comparison of the groups, the Chi-square test, Kruskal Wallis test, ANOVA test, and Mann-Whitney U test were used appopriately. To study the association between alleles and genotypes of SNPs, logistic regression analysis was done by calculating Odds ratio (OR) with 95% confidence interval (CI). The difference between the values reflected statistical significance when the P value was ≤ 0.05. Ethical clearance statement This study was approved by the Institutional Ethics Committee. Ref. No. KIMSDU/IFC/03/2019 Protocol no. 0575/2018-2019. Dated 09/07/2019. Written informed consent was obtained for participation in the study and use of the patient data for research and educational purposes. RESULTS In the present study, a total of 375 patients were included. Clinical characteristics and genotype distribution of ACE and AGT gene polymorphism in the three groups as defined earlier are displayed in Table 2. Demographic data were not included here as it has been already published in our previous article (unpublished article). Serum urea and creatinine levels were significantly higher (P = 0.000) in the DN group compared to the DR and DM groups. Systolic as well as diastolic blood pressure were significantly higher (P < 0.05) in the DR and DN groups compared to the DM group. Table 2General characteristics, biochemical parameters, and genotype distribution of ACE and AGT gene polymorphism in the groupsVariablesGroup 1 (DM) (n=125)Group 2 (DR) (n=125)Group 3 (DN) (n=125) P P Systolic BP (mm of Hg)130 (100-190)b,c140 (120-200)a150 (110-210)a0.001*Diastolic BP (mm of Hg)80 (60-100)b,c90 (70-110)a90 (70-100)a0.002*Serum urea (mg/dl)33.49±11.69c29.55±12.07c107.58±41.7a,b0.000*Serum creatinine (mg/dl)1.19±0.64c1.08±0.75c5.64±2.84a,b0.000*ACE ins/del II50 (40.0%)29 (23.2%)33 (26.4%) DD27 (21.6%)45 (36.0%)42 (33.6%)0.003d* ID48 (38.4%)51 (40.8%)50 (40.0%)0.110e0.020f*AGT Met235Thr TT54 (43.2%)28 (22.4%)30 (24%) CC23 (18.4%)24 (19.2%)27 (21.6%)0.067d TC48 (38.4%)73 (58.4%)68 (54.4%)0.000e*0.002f*Data were stated in terms of mean±SD, median with range, and numbers (percentage). aSignificantly different from Group 1, bsignificantly different from Group 2, csignificantly different from Group 3, dP value for comparison of wild vs mutant genotypes in the groups, eP value for comparison of wild vs heterozygous genotypes in the groups, and fP value for comparison of all genotypes in the groups. *Significant P<0.05 General characteristics, biochemical parameters, and genotype distribution of ACE and AGT gene polymorphism in the groups Data were stated in terms of mean±SD, median with range, and numbers (percentage). aSignificantly different from Group 1, bsignificantly different from Group 2, csignificantly different from Group 3, dP value for comparison of wild vs mutant genotypes in the groups, eP value for comparison of wild vs heterozygous genotypes in the groups, and fP value for comparison of all genotypes in the groups. *Significant P<0.05 The frequency of the mutant DD genotype of the ACE gene was significantly higher among the DR and DN groups compared to wild II genotypes (P = 0.003). Also, a significant difference was found in the occurrence of different genotypes of ACE ins/del SNP among the groups (P = 0.020). The wild TT genotype of AGT Met235Thr SNP was more frequent in the DM group. The heterozygous TC genotypes were more frequently observed in DN and DR groups (P = 0.000). The overall frequency of different genotypes that is, TT, CC, and TC in the groups was significantly different (P = 0.002) [Table 2]. Comparison of genotypes and alleles distribution along with the co-dominant model for ACE and AGT gene polymorphisms in DM and DR groups and DM and DN groups are described in Table 3. Mutant D allele of ACE ins/del gene polymorphism was more frequently seen in DR & DN patients (OR: 1.87, 95%CI: 1.32-2.67, P = 0.007) (OR: 1.67, 95%CI: 1.17-2.38, P = 0.005). The C allele of AGT SNP was more frequently seen in DR & DN groups. In the DM and DR groups, we observed significant differences in co-dominant models (II vs DD and II vs ID). The co-dominant model of AGT Met235Thr SNP (TT vs TC) (OR: 2.93, 95%CI: 1.64-5.26, P = 0.000) was found significantly different in the DM and DR groups. For ACE gene polymorphism, a significant difference was observed between DM and DN groups in genotype distribution and co-dominant model (II vs DD) (OR: 2.36, 95%CI: 1.23-4.53, P = 0.010). In co-dominant models of AGT gene polymorphism (TT vs CC and TT vs TC), a significant difference was observed between the DM and DN groups. Table 3Genotypes and alleles distribution, Co-dominant Models for ACE ins/del and AGT Met235Thr gene polymorphisms in DM, DR, and DN groupsSNPGenotype/AlleleDM (n=125)DR (n=125) P OR (95% CI)ACE ins/del GenotypeDD/ID/II27/48/5045/51/290.006 * AlleleD/I102/148141/1090.007*1.87(1.32-2.67) Co-dominant ModelII50 (40%)29 (23.2%)ReferenceDD27 (21.6%)45 (36%)0.002*2.87 (1.48-5.56)ID48 (38.4%)51 (40.8%)0.049*1.83 (1.001-3.35)AGT Met235Thr GenotypeCC/TC/TT23/48/5424/73/280.001* AlleleC/T94/156121/1290.018*1.55 (1.09-2.22) Co-dominant ModelTT54 (43.2%)28 (22.4%)ReferenceCC23 (18.4%)24 (19.2%)0.0612.01 (0.97-4.18)TC48 (38.4%)73 (58.4%)0.000*2.93 (1.64-5.26) DM (n=125) DN (n=125) P OR (95% CI) ACE ins/del GenotypeDD/ID/II27/48/5042/50/330.034* AlleleD/I102/148134/1160.005*1.67 (1.17-2.38) Co-dominant ModelII50 (40%)33 (26.4%)ReferenceDD27 (21.6%)42 (33.6%)0.010*2.36 (1.23-4.53)ID48 (38.4%)50 (40%)0.1311.58 (0.87-2.85)AGT Met235Thr GenotypeCC/TC/TT23/48/5427/68/300.005* AlleleC/T94/156122/1280.014*1.58 (1.1-2.25) Co-dominant ModelTT54 (43.2%)30 (24%)ReferenceCC23 (18.4%)27 (21.6%)0.040*2.11 (1.04-4.31)TC48 (38.4%)68 (54.4%)0.002*2.55 (1.43-4.55)SNP: Single nucleotide polymorphism, OR: Odds Ratio, CI: Confidence Interval, *Significant P<0.05 Genotypes and alleles distribution, Co-dominant Models for ACE ins/del and AGT Met235Thr gene polymorphisms in DM, DR, and DN groups SNP: Single nucleotide polymorphism, OR: Odds Ratio, CI: Confidence Interval, *Significant P<0.05 DISCUSSION Today, India is facing an immense challenge in terms of a rising number of diabetic patients. This may be the tip of the iceberg as below that pre-diabetic patients might be large in number. Even though research is going on, we have yet to discover a genetic predisposition to type 2 diabetes mellitus and its related complications. The renin-angiotensin-aldosterone system is a powerful regulator of arterial blood pressure and atherosclerosis and an apparent correlation was discovered between it and complications of diabetes.[71617] In the present research, we investigated the interrelation of ins/del SNP of the ACE gene and Met235Thr SNP of the AGT gene which are part of RAAS pathway genes with diabetic retinopathy and nephropathy. In a total of 375 T2DM patients, we found considerably higher systolic and diastolic pressure as well as higher serum urea and creatinine among DN patients compared to other groups which is consistent with the observations in other studies.[1518] The frequency of the mutant DD genotype of the ACE gene was notably higher in the DN group. The presence of the DD genotype showed an increased risk of development of diabetic nephropathy (OR: 2.36, 95%CI: 1.23-4.53, P = 0.010). This is quite well matched with data from the study by Rigat B et al.,[19] where increased serum ACE levels were closely related to deletion polymorphism in the ACE gene. This polymorphism could have led to increased production of angiotensin II from angiotensin I in blood. Angiotensin II increases the intra-glomerular pressure, glomerular filtration rate, and production of several cytokine mediators ultimately causing glomerulonephritis. This shows the connecting link between D polymorphism and the development of nephropathy in T2DM patients.[19] A Meta-analysis by Wang F et al.[6] revealed a remarkable association between DD polymorphism and DN which support our observations. Still, there are diverse findings about the association of ACE ins/del polymorphism and the risk of DN in different populations. Some studies reported a strong association[2021] while some studies did not find this association.[2223] Also in India, contrast results were documented with Naresh VV et al.[24] confirming a positive association for D allele and DN and Prasad P et al.[15] displaying no association. The D allele and DD genotype of ins/del SNP of the ACE gene appear to be highly predisposing to retinopathy (OR: 1.87, 95%CI: 1.32-2.67, P = 0.007 and OR: 2.87, 95%CI: 1.48-5.56, P = 0.002, respectively). Our findings are further supported by the studies reporting a conclusive association between RAS gene polymorphism and initiation as well as the progression of DR, suggesting the role of RAS polymorphism as a risk factor in both non-proliferative DR and proliferative DR.[2526] A meta-analysis by Luo S et al.[8] discovered that ACE I/D gene polymorphism might contribute to DR development, especially in the Asian T2DM group. Conflicting results without any significant association between ACE gene polymorphism and DR were also displayed.[79102728] Met235Thr SNP in AGT showed a strong genotypic association with diabetic retinopathy along with nephropathy. Similar to earlier observation[15] we found an allelic association with the DN group. The presence of mutant CC genotype and heterozygous TC showed increased risk of nephropathy in T2DM patients (OR: 2.11, 95%CI: 1.04-4.31, P = 0.040 and OR: 2.55, 95%CI: 1.43-4.55, P = 0.002, respectively) while TC genotype increases the risk of diabetic retinopathy (OR: 2.93, 95%CI: 1.64-5.26, P = 0.000). Our findings regarding DN are consistent with the previous study[15] showing a very significant relationship of Met235Thr SNP in AGT gene with renal insufficiency in type 2 diabetic patients in the Indian population (OR: 2.68, 95%CI: 2.01-3.57 for Thr allele and OR: 2.94, 95%CI: 1.88-4.59, for Thr/Thr genotype). However previous studies by Schmidt S et al.[16] and Makuc J et al.[18] indicated no association between this SNP and DN. We would be cautious with our findings regarding the association of TC genotype with DR due to the low power of our sample and these findings need to be confirmed in studies with large sample sizes. In the Chinese population, AGT Met235Thr gene polymorphism did not show a connection with the progress of diabetes advancing into retinopathy.[27] As far as we are aware, ours was the first study that attempted to discover the association between ACE ins/del and AGT Met235Thr SNPs with DR and DN risk in rural Maharashtra. Since this was a single-center cross-sectional study, the collection of large data was not possible. Although the present study fulfills most of the criteria such as sample size and selection criteria, a larger sample size is needed to confirm some of the findings in the study. CONCLUSION The presence of the DD genotype in the ACE ins/del SNP showed an increased risk of development of diabetic nephropathy and retinopathy while the CC genotype in AGT Met235Thr showed an increased risk of nephropathy in T2DM patients. The use of these SNPs as markers for the predicting tendency to develop nephropathy and retinopathy in type 2 diabetic patients in the Indian Population would be beneficial for prevention and cure in the future. Anyway, we have to do studies in large sample sizes in multiple centers across the country for confirmation of some results. Author contributions Concept and design by VSP, KDD, AVS; Clinical studies by VSP, PSP; Experimental Studies by VSP, KDD, SKP; Data acquisition by VSP, KDD, SKP, PSP; Data analysis by VSP, KDD; Statistical analysis by VSP, SKP; Manuscript preparation by VSP, SKP; Manuscript editing and review by all. All authors read and approved the final manuscript. Conflicts of interest There are no conflicts of interest.